Ruxolitinib

Description

Product name: Ruxolitinib

Synonym: (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile,

Catalog #: 8333063

Purity: 98%

CAS No.: 941678-49-5

Molecular Formula: C17H18N6

Molecular Weight: 306.37

Compound ID: 25126798

Description: Ruxolitinib, (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate, has a molecular weight of 404.36 kDa. Ruxolitinib is soluble in aqueous solutions at pH 1–8. Ruxolitinib tablets are stable at 20–25°C and tolerate brief exposures to temperatures outside this range, if they stay within 15–30°C. Ruxolitinib is an equipotent inhibitor of JAK1 [mean half maximal inhibitory concentration (IC50) = 3.3 nM] and JAK2 (mean IC50 = 2.8 nM) in vitro, with at least 100-fold less inhibitory activity against JAK3. Ruxolitinib has a terminal half-life of approximately 3h and is predominantly metabolized by CYP3A4 and to a lesser extent by CYP2C9, with 74 and 22 % of a ruxolitinib dose recovered in urine and feces, respectively, within 24 h of oral administration in healthy human volunteers (<1 % was unchanged drug).

 

Usage: For Scientific Research Use Only, Not for Human Use.